Abstract
Peanut allergy immunotherapy (PA-IT) is emerging as a viable treatment option for peanut allergic patients. Various routes of PA-IT administration have been investigated in the search for an efficient and safe IT approach. Here, we performed a comprehensive investigation of the humoral immune response during the mucosal administration of peanut protein extract (PPE) via oral (O), intragastric (IG) and sublingual (SL) routes in a Brown Norway rat model of PA-IT.
| Original language | English |
|---|---|
| Article number | 000939 |
| Journal | Allergy: European Journal of Allergy and Clinical Immunology |
| Volume | 79 |
| Issue number | S113 |
| Pages (from-to) | 244-245 |
| Number of pages | 2 |
| ISSN | 0105-4538 |
| Publication status | Published - 2024 |
| Event | European Academy of Allergy and Clinical Immunology Hybrid Congress 2024 - Valencia, Spain Duration: 31 May 2024 → 3 Jun 2024 |
Conference
| Conference | European Academy of Allergy and Clinical Immunology Hybrid Congress 2024 |
|---|---|
| Country/Territory | Spain |
| City | Valencia |
| Period | 31/05/2024 → 03/06/2024 |
Fingerprint
Dive into the research topics of 'The peanut-specific antibody profile during three different mucosal immunotherapies for peanut allergy in brown Norway rats'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver